InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

Core Points - InflaRx N.V. has received a notice from Nasdaq indicating that its common shares have closed below the minimum bid price of $1.00 for the last 30 consecutive business days [1] - The company has until January 7, 2026, to regain compliance with the Minimum Bid Price Rule, with the possibility of transferring to the Nasdaq Capital Market for an additional compliance period [2] - The notice does not have an immediate effect on the listing or trading of the company's shares, and InflaRx plans to monitor its share price and explore options for compliance [3] Company Overview - InflaRx is a biopharmaceutical company focused on developing anti-inflammatory therapeutics by targeting the complement system, specifically through its proprietary anti-C5a and anti-C5a receptor technologies [4] - The company has developed vilobelimab, a first-in-class anti-C5a monoclonal antibody, and is also working on INF904, an orally administered small molecule inhibitor [4] - Founded in 2007, InflaRx has offices in Jena and Munich, Germany, and Ann Arbor, MI, USA [5]